Leap Therapeutics (NASDAQ:LPTX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $5.50 price objective on the stock. HC Wainwright's target price suggests a potential upside of 94.35% from the stock's current price.
Leap Therapeutics Trading Down 2.1 %
Shares of NASDAQ:LPTX traded down $0.06 on Friday, reaching $2.83. 211,811 shares of the company's stock were exchanged, compared to its average volume of 238,323. Leap Therapeutics has a twelve month low of $1.34 and a twelve month high of $5.00. The company has a fifty day moving average of $2.94 and a 200-day moving average of $2.58. The company has a market capitalization of $72.45 million, a price-to-earnings ratio of -1.50 and a beta of 0.22.
Leap Therapeutics (NASDAQ:LPTX - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.10). As a group, equities research analysts forecast that Leap Therapeutics will post -1.84 EPS for the current fiscal year.
Institutional Investors Weigh In On Leap Therapeutics
A number of large investors have recently bought and sold shares of the company. Valence8 US LP acquired a new stake in shares of Leap Therapeutics during the 3rd quarter worth approximately $48,000. HighTower Advisors LLC bought a new position in shares of Leap Therapeutics in the 3rd quarter valued at $65,000. Marshall Wace LLP lifted its position in shares of Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock worth $156,000 after buying an additional 58,094 shares during the last quarter. Key Client Fiduciary Advisors LLC lifted its position in shares of Leap Therapeutics by 22.2% during the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 284,856 shares of the company's stock worth $558,000 after buying an additional 51,838 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Leap Therapeutics by 349.3% in the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company's stock valued at $750,000 after buying an additional 219,563 shares in the last quarter. 30.46% of the stock is currently owned by institutional investors and hedge funds.
Leap Therapeutics Company Profile
(
Get Free Report)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Read More
Before you consider Leap Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Leap Therapeutics wasn't on the list.
While Leap Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
